BRIEF-Hbm Holdings Says Unit Entering T-Cell Engager Discovery Collaboration With Candid Therapeutics

Reuters

16 Dec 2024

BRIEF-Hbm Holdings Says Unit Entering T-Cell Engager Discovery Collaboration With Candid <a href="https://laohu8.com/S/LENZ">Therapeutics</a>

Dec 16 (Reuters) - Hbm Holdings Ltd 2142.HK:

UNIT ENTERING T-CELL ENGAGER DISCOVERY COLLABORATION WITH CANDID THERAPEUTICS
NONA BIOSCIENCES WILL BE ELIGIBLE TO RECEIVE UPFRONT AND POTENTIAL MILESTONE PAYMENTS OF UP TO US$320 MILLION

Further company coverage: 2142.HK

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.tigerhkgo.com/news/2491561826"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2491561826\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2491561826?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-16 23:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2491561826","market":"us","top_or_hot":-1,"title":"BRIEF-Hbm Holdings Says Unit Entering T-Cell Engager Discovery Collaboration With Candid Therapeutics","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Hbm Holdings Says Unit Entering T-Cell Engager Discovery Collaboration With Candid <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a></title></head><body><p><span>Dec 16 (Reuters)</span><span> - </span>Hbm Holdings Ltd <span>2142.HK</span>:</p><ul><li><p>UNIT ENTERING T-CELL ENGAGER DISCOVERY COLLABORATION WITH CANDID THERAPEUTICS</p></li><li><p>NONA BIOSCIENCES WILL BE ELIGIBLE TO RECEIVE UPFRONT AND POTENTIAL MILESTONE PAYMENTS OF UP TO US$320 MILLION</p></li></ul><p>Further company coverage: <span>2142.HK</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>BRIEF-Hbm Holdings Says Unit Entering T-Cell Engager Discovery Collaboration With Candid Therapeutics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Hbm Holdings Says Unit Entering T-Cell Engager Discovery Collaboration With Candid Therapeutics\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2024-12-16 23:33</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<title>BRIEF-Hbm Holdings Says Unit Entering T-Cell Engager Discovery Collaboration With Candid <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a></title><p><span>Dec 16 (Reuters)</span><span> - </span>Hbm Holdings Ltd <span>2142.HK</span>:</p><ul><li><p>UNIT ENTERING T-CELL ENGAGER DISCOVERY COLLABORATION WITH CANDID THERAPEUTICS</p></li><li><p>NONA BIOSCIENCES WILL BE ELIGIBLE TO RECEIVE UPFRONT AND POTENTIAL MILESTONE PAYMENTS OF UP TO US$320 MILLION</p></li></ul><p>Further company coverage: <span>2142.HK</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02142","symbol_name":"和铂医药-B","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241216:nFWN3NH0P8:1","article_id":"2491561826","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2491561826","pubTimestamp":1734363195,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Hbm Holdings Says Unit Entering T-Cell Engager Discovery Collaboration With Candid TherapeuticsDec 16  - Hbm Holdings Ltd 2142.HK:UNIT ENTERING T-CELL ENGAGER DISCOVERY COLLABORATION WITH CANDID THERAPEUTICSNONA BIOSCIENCES WILL BE ELIGIBLE TO RECEIVE UPFRONT AND POTENTIAL MILESTONE PAYMENTS OF UP TO US$320 MILLIONFurther company coverage: 2142.HK ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02142":"和铂医药-B","BK1583":"高瓴概念","BK1574":"生物医药B类股","BK1161":"生物科技"},"translate_title":"简介-Hbm Holdings表示该部门将与Candid Therapeutics开展T细胞接合剂发现合作","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02142":0.9},"content_text":"BRIEF-Hbm Holdings Says Unit Entering T-Cell Engager Discovery Collaboration With Candid TherapeuticsDec 16 (Reuters) - Hbm Holdings Ltd 2142.HK:UNIT ENTERING T-CELL ENGAGER DISCOVERY COLLABORATION WITH CANDID THERAPEUTICSNONA BIOSCIENCES WILL BE ELIGIBLE TO RECEIVE UPFRONT AND POTENTIAL MILESTONE PAYMENTS OF UP TO US$320 MILLIONFurther company coverage: 2142.HK ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1}}}